SYS6010 versus standard single-drug therapy for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called SYS6010 against standard single-drug options in people with head and neck cancer that has returned or spread after prior treatment. The goal is to see if SYS6010 can shrink tumors or slow the disease better than the usual choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of head and neck squamous cell carcinoma (a type of cancer that starts in the mouth, throat, or voice box).
- Your cancer must have grown or returned after you have already tried both a platinum-based chemotherapy (like cisplatin or carboplatin) and a PD-(L)1 inhibitor (like pembrolizumab or nivolumab).
- You must have at least one tumor that can be measured on a scan.
- You must be able to take care of yourself (fully active or only limited in strenuous activity).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three medicines (SYS6002, JMT101, and Enlonstobart) for people with head and neck cancer that has come back or spread and cannot be removed by surgery or radiation. The goal is to see if this treatment helps shrink tumors or slow the disease.
This trial is testing a new combination treatment, SYS6010 plus enlonstobart, for people with head and neck squamous cell carcinoma that has come back or spread. It aims to see if this combination works better than enlonstobart alone.
This trial tests two new drugs, BL-B01D1 and SI-B003, alone or together, for people with head and neck squamous cell carcinoma that has come back or spread. It may also include other solid tumors. The goal is to see if these drugs can shrink tumors or slow their growth.
This trial tests a new drug combination (BL-B01D1 plus a PD-1 inhibitor) for people with advanced head and neck cancer or other solid tumors that have come back or spread. It aims to see if the treatment can help shrink tumors or slow the disease.
This trial tests a new drug, HS-20093, in people with head and neck squamous cell carcinoma or other solid tumors that have worsened after standard treatments. The goal is to see if the drug can help shrink or slow the growth of these cancers.
This trial tests a new drug called SYS6002 against standard chemotherapy for cervical cancer that has come back or spread. It aims to see if SYS6002 works better for people who have already tried platinum chemo and immunotherapy.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.